{
  "docId": "019de072-122c-721c-8b62-3522a74ffc66",
  "docSlug": "bcca0cb7dade19d9f637477238714c68",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 33,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a process flow diagram to illustrate the clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-122c-721c-8b62-3522a74ffc66/22",
  "deckHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66",
  "deckJsonHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66.json",
  "deckAnchorHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.025
      },
      "kind": "diagram",
      "text": "Trial flow diagram showing patient enrollment, randomization (2:1), treatment arms (Pegzilarginase vs Placebo), and long-term extension.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b9e1e41-90cc-4263-acac-1d17afc76503",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "Double-blind portion of trial complete – topline data announced December 2021",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d295a46b-af09-45dd-bebc-896649862ba8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.089
      },
      "kind": "source-note",
      "text": "Dosing is weekly and, if needed, dose is modified based on plasma arginine levels with maintenance of blinding. The first 8 weeks of the open-label extension will be blinded. All study participants remain on current disease management for the duration of the trial. Dose adjustments in the double-blind treatment period can be made to optimize plasma arginine control for levels outside the range of 50-150µM. If needed, weekly doses can be increased to 0.15 and 0.2 mg/kg or reduced to 0.05mg/kg. ARG1-D = Arginase 1 Deficiency; IV = intravenous; R = randomized.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eb58035-525e-4d69-b8ba-33ae44b379e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.065
      },
      "kind": "table",
      "text": "Key Endpoints and Analysis table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "126844c4-3eab-4488-a8da-f6728ffcc27b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "PEACE Phase 3 Study Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11d57288-e854-4e98-b210-f0c2fbdea9cc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Hypothesis-Driven Structure",
      "slug": "hypothesis-driven-structure",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "2dd974e5-931c-47fb-beb3-0559c0509f63",
      "evidence": "Double-blind portion of trial complete – topline data announced December 2021",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "8b0dc647-4adb-404d-82a4-2239c4a7ad9f",
      "evidence": "Standardized representation of patient flow, randomization, and endpoints in a clinical study.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 26,
      "from": 21,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "9cc0cacb-1c5c-40f5-a519-d219894ab0a2",
      "evidence": "The deck provides clinical data supporting the effectiveness of Pegzilarginase",
      "position": 1,
      "objective": "Show the potential of Pegzilarginase to improve patient outcomes",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}